Conjugate with target-finding ligand and use thereof
Described is a conjugate of agent complex and at least one target-finding ligand, where the agent complex comprises an agent encapsulated by an encapsulation material and where the target-finding ligand is a prostacyclin analog, and the use of the conjugate.
1. A conjugate of (a) an agent complex and (b) at least one target finding ligand,
wherein the agent complex comprises a nanoparticle or nanocapsule comprising (i) an agent encapsulated with (ii) a cationic polymer or serum albumin,
wherein the at least one target-finding ligand is iloprost or treprostinil,
wherein the at least one target-finding ligand is bonded to the cationic polymer or serum albumin, and
wherein the at least one target finding ligand is not the agent.
2. The conjugate of claim 1 , wherein the agent is a nucleic acid or a derivative thereof, a peptide, polypeptide or derivative thereof, an active substance or a tracer.
3. The conjugate of claim 2 , wherein the nucleic acid is a DNA or RNA whose lack or deficiency causes a disease or is a DNA or RNA which encodes a polypeptide whose lack or deficiency causes a disease or which has an immunomodulatory activity.
4. The conjugate of claim 2 , wherein the agent is a peptide or polypeptide whose lack or deficiency causes a disease or which has an immunomodulatory activity.
5. The conjugate of claim 2 , wherein the agent is a product which compensates for a protein defect or lack of protein and is selected from among nucleic acid, protein, protein derivative or protein fragment or a pharmaceutical which is active in the lungs or a mixture thereof.
6. The conjugate of claim 2 , wherein the active substance is an anti-inflammatory active substance or a steroid.
7. The conjugate of claim 1 , wherein the agent is a reporter molecule.
8. The conjugate of claim 1 , wherein the nanoparticle or nanocapsule comprises serum albumin.
9. The conjugate of claim 1 wherein the nanoparticle or nanocapsule comprises a cationic polymer selected from spermine or polyethyleneimine.
10. The conjugate of claim 1 , further comprising that the agent complex is pegylated.
11. The conjugate of claim 9 , wherein the agent is DNA, and the cationic polymer and DNA are present in a ratio of from 10:1 to 1:20, when measured as a molar ratio of polymer nitrogen content to DNA phosphate content.
12. A method of treating a pulmonary disease, comprising: administering to the lungs a conjugate comprising (i) a nanoparticle or nanocapsule comprising an agent encapsulated with a cationic polymer or serum albumin and (ii) at least one target-finding ligand that is iloprost or treprostinil,
wherein the at least one target-finding ligand is not the agent,
wherein the at least one target-finding ligand is bonded to the cationic polymer or serum albumin, and
wherein the at least one target-finding ligand binds to bronchial and/or alveolar epithelial cells,
thereby transporting the conjugate into the bronchial and/or alveolar epithelial cells.
13. A therapeutic composition for the treatment of pulmonary disorders, comprising the conjugate of claim 1 and a pharmaceutical excipient in a form suitable for inhalation.
14. The conjugate of claim 1 , wherein the cationic polymer is polyethyleneimine, and the at least one target finding ligand is iloprost, and wherein there is a degree coupling of iloprost and polyethyleneimine of from 2 to 16 ligands per polymer.
15. The conjugate of claim 14 , wherein the degree of coupling of iloprost and polyethyleneimine is from 2 to 5 ligands per polymer.
16. The conjugate of claim 14 , wherein the degree of coupling of iloprost and polyethyleneimine is 5 ligands per polymer.
17. The conjugate of claim 1 , wherein (i) the agent is DNA, (ii) the cationic polymer is polyethyleneimine, (iii) the at least one target finding agent is iloprost,
wherein there is a degree of coupling of iloprost and polyethyleneimine of 5 ligands per polymer, and
wherein polyethyleneimine and DNA are present in a ratio of 4:1, when measured as a molar ratio of polymer nitrogen content to DNA phosphate content.
18. A conjugate of (a) an agent complex and (b) at least one target finding ligand,
wherein the agent complex comprises a nanoparticle or nanocapsule comprising (i) an agent with (ii) a cationic polymer,
wherein the at least one target-finding ligand is iloprost or treprostinil, and,
wherein there is a degree of coupling of iloprost or treprostinil, and the cationic polymer of 15 ligands per polymer or less.
19. The conjugate of claim 1 , wherein the target-finding ligand is covalently bonded to the cationic polymer or serum albumin.
20. A conjugate of (a) an agent complex and (b) at least one target finding ligand, wherein the agent complex comprises a nanoparticle or nanocapsule comprising (i) an agent with (ii) a cationic polymer,
wherein the at least one target-finding ligand is not the agent and is bonded to the cationic polymer,
wherein the cationic polymer is polyethyleneimine, and the at least one target finding ligand is iloprost, and
wherein there is a degree of coupling of iloprost and polyethyleneimine of from 2 to 16 ligands per polymer.
21. The conjugate of claim 20 , wherein the degree of coupling of iloprost and polyethyleneimine is from 2 to 5 ligands per polymer.
22. The conjugate of claim 20 , wherein the degree of coupling of iloprost and polyethyleneimine is 5 ligands per polymer.
23. The conjugate of claim 20 , wherein (i) the agent is DNA,
wherein the degree of coupling of iloprost and polyethyleneimine is 5 ligands per polymer, and
wherein polyethyleneimine and DNA are present in a ratio of 4:1, when measured as a molar ratio of polymer nitrogen content to DNA phosphate content.
24. The conjugate of claim 1 , wherein the agent complex comprises a nanoparticle or nanocapsule comprising (i) an agent encapsulated with (ii) a cationic polymer, and
wherein the cationic polymer comprises polyethyleneimine.